Tezepelumab (bronchial asthma, patients aged ≥ 12 years)

Subject:

• Active Substance: Tezepelumab
• Name: Tezspire®
• Therapeutic area: Asthma
• Pharmaceutical company: AstraZeneca GmbH

Time table:

• Start: 15.11.2022
• Publication of assessment: 15.02.2023
• End of public hearing: 09.03.2023
• Final decision by G-BA: middle of May 2023

Comparative therapy:

1. Adolescents aged 12 to 17 years: A patient-individual therapy depending on the previous therapy choosing from:
   - high-dose ICS and LABA and LAMA OR
   - high-dose ICS and LABA and, if applicable, LAMA and omalizumab, provided that the criteria necessary for the use of omalizumab are met OR
   - high-dose ICS and LABA and, if applicable, LAMA and mepolizumab or dupiliumab, if the necessary criteria for the use of omalizumab are not met
2. Adults: A patient-individual therapy depending on the previous therapy and the pathogenesis of asthma choosing from:
   - high-dose ICS and LABA and LAMA OR
   - high-dose ICS and LABA and, if applicable, LAMA and omalizumab, provided that the criteria necessary for the use of omalizumab are met OR
   - high-dose ICS and LABA and, if applicable, LAMA and mepolizumab or reslizumab or benralizumab or dupilumab, provided that the criteria necessary for the use of the respective antibodies are met